Just submitted my #HematologyOncologyfellowship application! Grateful to my mentors, co-residents, and the incredible leadership at my program for their support. Excited for what lies ahead! AAMC ID: 15136517 Moath Albliwi #HemeOnc #Match2026 #FutureOncologist @FairviewIMRes

Honored to Receive the 2025 ASH Abstract Achievement Award - Moath Ahmad Albliwi @moathalbliwi @ASH_hematology https://t.co/yIykmotKYV #Cancer #Medicine #Health #Oncology #OncoDaily #ASH25 #MedX #MedNews #MedEd

Excited to announce that I’ve been selected for the @ASH_hematology Abstract Achievement Award! 🎉 Looking forward to connecting with friends and colleagues this December 6–9, 2025, in Orlando, Florida!! Let's connect! #ASH2025 #HematOncology #MedTwitter #CCF #MedicalResearch

Revumenib is now @US_FDA ✅ for R/R AML w/ NPM1 mutation (approved for KMT2A translocation previously). - ORR 46.9% - Response seen in all subgroups (comutations, previous HSCT, or high number of prior lines of Rx). #HemeTwitter @beatalleukemia @LeukDocJZ 👏👏

Honored to share that I scored in the 98th percentile nationwide among #InternalMedicine residents on the In-Training Exam (ITE), as reported by the American College of Physicians (ACP). Grateful for the journey and excited for what’s ahead!

Lobular breast cancer requires specialized care ⁦@ClevelandClinic⁩ Comprehensive Lobular Breast Cancer Program brings together experts dedicated to advancing care, treatment, and research for these patients. #CleClinicCancer #Lobular #BreastCancer https://t.co/UYIR7IwxLE

@moathalbliwi We would like to inform you that your post has been published on Hemostasis Today. Thank you for sharing. https://t.co/vOiBWnzOK9

@HemOncToday @oncodaily @FairviewIMRes

I am thrilled to share that we have 17 abstracts accepted at #ASH2025! I’ll be presenting 4 major posters in Orlando. Excited to connect with colleagues & grateful to my mentors for their support! 🙏🎉 #Hematology #Oncology #MedTwitter #MedicalEducation

Hi #MedTwitter! I’m Forat, a US-IMG from Jordan 🇯🇴 and applying to #InternalMedicine for #Match2026. I am drawn to intellectual depth and complexity of Internal Medicine. I enjoy watching Real madrid, playing snooker, and mentoring people. AAMC ID: 15929273 Let’s connect !

From Tracking a Bitcoin Chart to Crafting a Differential Diagnosis.🩺📈 Mustafa here! I'm a Non-US IMG from Jordan 🇯🇴 applying to #InternalMedicine residency for #Match2026. In my free time, I enjoy trading & analyzing crypto 📊, cheering on Barcelona & Al-Hussein Irbid ⚽️,

Honored to receive a Reviewer Certificate from Scientific Reports (Springer Nature) for my contribution in 2025. Grateful for the chance to support the peer-review process and advance science in #Hematology #Oncology #PeerReview #ScientificReports

🎉🎉 Please join me to congratulate my fantastic mentee @moathalbliwi and research team, who worked hard to conduct this nicely designed study !! @moathalbliwi is applying to Hematology/ Oncology fellowship and deserves all the attention and support her can get !! 🎉🎉

Thrilled to share my first-author publication in CLML! 🚨 📖 Comparative Outcomes of Intensive Chemotherapy vs Venetoclax + HMA in AML patients aged 60–75: A Propensity Score–Adjusted Cohort Study @moaathmustafaal 👉 https://t.co/Nz1QUD2tzl #AML #Leukemia #Hematology #Oncology

Precemtabart tocentecan, an anti-CEACAM5 ADC, is active in heavily pretreated metastatic colorectal cancer—median PFS is 6.9 months, and 72% disease control at 12 weeks. First CRC cohort reported in @NatureMedicine. #crcsm

New in Blood Cancer Journal 📢 We analyzed AE profiles of BCMA vs GPRC5D/FcRH5 bispecifics in 2,300+ MM patients across 22 trials. 🧪 Insights to guide safer myeloma care. https://t.co/GV0BXJsxhR #MultipleMyeloma #BispecificAntibodies @FaizAnwerMD1, thank you for the mentorship

Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma https://t.co/Tp4RiQefjh

Outstanding candidate with a strong track record. Highly recommended! @moathalbliwi

Honored to see our #ASCO25 abstract featured by @Healio. These findings challenge long-held assumptions and open new doors in understanding the “obesity paradox” in immunotherapy outcomes. Grateful for the opportunity to contribute. @moaathmustafaal #Immunotherapy #BMI

🚨 Just Submitted my #GIFellowship application! 💩 From Egypt to Houston to Cleveland, thankful for the journey. Grateful for my mentors. You’re my heros. Dedicated to advancing equitable care for liver patients. 📌AAMC ID: 13695481 🩺 Excited for what’s ahead! 💡 #ERAS2025